Rump L C, Oberhauser V, von Kügelgen I
Medizinische Universitätsklinik, Innere Medizin IV, Freiburg, Germany.
Kidney Int. 1998 Aug;54(2):473-81. doi: 10.1046/j.1523-1755.1998.00002.x.
Adenosine triphosphate (ATP) and its metabolites including adenosine modulate renal vascular tone under physiological and pathophysiological conditions. Their effects are brought about by activation of membrane bound P1- and P2-purinoceptors located on smooth muscle and endothelial cells. In this study we analyzed the purinoceptor mediated dilation of rabbit and human renal arteries, and evaluated the possible involvement of endothelium-derived relaxing factors.
Segments of rabbit and human renal arteries were incubated and perfused with medium containing indomethacin. After preconstriction, drug induced changes in the vessel diameters were measured by a photoelectric device.
ATP (EC50 = 1 mumol/liter), added intraluminally, caused maximal vasodilation of 80 to 100% of the preconstriction response in both species. This effect was inhibited by the P1-purinoceptor antagonist 8-p-(sulphophenyl)theophylline (100 mumol/liter), suggesting that it was in part due to breakdown of ATP to adenosine. The nature of purinoceptor mediated renal vasodilation was studied further in rabbit renal arteries. Adenosine (EC50 = 1 mumol/liter) as well as the P2Y-receptor agonists ADP beta S (EC50 = 0.4 mumol/liter) and 2-MeSATP (EC50 = 0.2 mumol/liter) dilated the arteries by 80 to 100%. The effects of 2-MeSATP, which were to a much lesser extent that of ADP beta S but not that of adenosine, were attenuated by the P2Y-antagonist reactive blue 2 (3 mumol/liter). Removal of the endothelium almost abolished the vasodilation induced by adenosine and ATP. In contrast, these dilator response were only slightly attenuated by the nitric oxide synthase blockers NG-nitro-L-arginine methyl ester and NG-nitro-L-arginine (300 mumol/liter each), whereas acetylcholine and 2-MeSATP induced dilation was markedly reduced by NG-nitro-L-arginine methyl ester.
P1-purinoceptors activated by adenosine dilate rabbit renal arteries by an endothelium-derived relaxing factor that appears to be distinct from nitric oxide. In contrast, P2Y-purinoceptor induced renal dilation is mediated by nitric oxide. ATP, the physiological activator of P2Y-purinoceptors, is rapidly broken down to adenosine in rabbit and human renal arteries. Therefore, in rabbit and human renal arteries the vasodilatory effect of exogenous ATP mainly results from P1-purinoceptor activation probably through its breakdown product, adenosine.
三磷酸腺苷(ATP)及其代谢产物包括腺苷,在生理和病理生理条件下调节肾血管张力。它们的作用是通过激活位于平滑肌和内皮细胞上的膜结合P1和P2嘌呤受体来实现的。在本研究中,我们分析了嘌呤受体介导的兔和人肾动脉舒张,并评估了内皮源性舒张因子可能的参与情况。
将兔和人肾动脉段用含吲哚美辛的培养基孵育并灌注。预收缩后,用光电装置测量药物引起的血管直径变化。
腔内加入ATP(EC50 = 1 μmol/升),在两种动物中均引起最大舒张,达预收缩反应的80%至100%。P1嘌呤受体拮抗剂8 - p -(磺苯基)茶碱(100 μmol/升)可抑制此效应,提示其部分是由于ATP分解为腺苷所致。在兔肾动脉中进一步研究了嘌呤受体介导的肾血管舒张的性质。腺苷(EC50 = 1 μmol/升)以及P2Y受体激动剂ADPβS(EC50 = 0.4 μmol/升)和2 - MeSATP(EC50 = 0.2 μmol/升)使动脉舒张80%至100%。2 - MeSATP的效应在程度上比ADPβS小得多,但比腺苷小,P2Y拮抗剂反应性蓝2(3 μmol/升)可减弱其效应。去除内皮几乎消除了腺苷和ATP诱导的血管舒张。相反,这些舒张反应仅被一氧化氮合酶阻滞剂NG - 硝基 - L - 精氨酸甲酯和NG - 硝基 - L - 精氨酸(各300 μmol/升)轻微减弱,而乙酰胆碱和2 - MeSATP诱导的舒张被NG - 硝基 - L - 精氨酸甲酯显著降低。
腺苷激活的P1嘌呤受体通过一种似乎不同于一氧化氮的内皮源性舒张因子使兔肾动脉舒张。相反,P2Y嘌呤受体诱导的肾舒张由一氧化氮介导。P2Y嘌呤受体的生理激活剂ATP在兔和人肾动脉中迅速分解为腺苷。因此,在兔和人肾动脉中,外源性ATP的血管舒张作用主要可能是通过其分解产物腺苷激活P1嘌呤受体所致。